Global Biomarker Partnering Terms and Agreements Directory 2010-2018

Dublin, April 18, 2018 -- The "Global Biomarker Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Biomarker Partnering Terms and Agreements 2010-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Key benefits

• In-depth understanding of biomarker deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of biomarker agreements with numerous real life case studies
• Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
• Access to most active biomarker dealmakers since 2010
• Insight into the terms included in a biomarker agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Most active Biomarker dealmakers
2.4. Biomarker partnering by deal type
2.5. Biomarker partnering by therapy area
2.6. Deal terms for Biomarker partnering
2.6.1 Biomarker partnering headline values
2.6.2 Biomarker deal upfront payments
2.6.3 Biomarker deal milestone payments
2.6.4 Biomarker royalty rates

Chapter 3 - Leading Biomarker deals

3.1. Introduction
3.2. Top Biomarker deals by value

Chapter 4 - Most active Biomarker dealmakers

4.1. Introduction
4.2. Most active Biomarker dealmakers
4.3. Most active Biomarker partnering company profiles

Chapter 5 - Biomarker contracts dealmaking directory

5.1. Introduction
5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Biomarker deals by company A-Z
Appendix 2 - Biomarker deals by stage of development
Appendix 3 - Biomarker deals by deal type

For more information about this report visit https://www.researchandmarkets.com/research/mw6nx8/global_biomarker?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biomarkers